Scholarlink

Objectives <p>We aimed to investigate the impact of the coronavirus disease-2019 pandemic on the prognosis of patients undergoing lung cancer surgery in a medium-burden region.</p> Methods <p>We retrospectively reviewed patients undergoing lung cancer surgery at a Japanese designated cancer hospital. Three-year time-to-progression (TTP) and overall survival (OS) were compared between the prepandemic (January 2018–March 2020, <i>n</i> = 333) and pandemic (April 2020–June 2022, <i>n</i> = 350) period, including subgroups analyses by pathological stage. Referral trends for all lung cancer and suspected lung cancer patients were also examined.</p> Results <p>There were no significant differences between the prepandemic and pandemic periods (TTP: 77.9% vs. 80.4%, <i>p</i> = 0.578; OS: 86.1% vs. 86.3%, <i>p</i> = 0.916), nor in pStage 0–I (TTP: 88.1% vs. 89.9%, <i>p</i> = 0.529; OS: 90.1% vs. 91.0%, <i>p</i> = 0.660) or pStage II (TTP: 67.3% vs. 78.2%, <i>p</i> = 0.471; OS: 78.7% vs. 82.6%, <i>p</i> = 0.736). However, TTP and OS during the pandemic were significantly lower in pStage III (TTP: 49.4% vs. 31.5%, <i>p</i> = 0.045, OS: 73.3% vs. 71.8%, <i>p</i> = 0.890) and IV (TTP: 12.5% vs. 25.0%, <i>p</i> = 0.668, OS: 87.5% vs. 29.2%, <i>p</i> = 0.023), respectively. During the pandemic, outside-referrals markedly decreased, while in-hospital referrals increased.</p> Conclusions <p>While overall surgical outcomes remained stable, stage-specific analyses demonstrated worse outcomes in advanced-stage disease during the pandemic. A reduction in outside referrals during the pandemic was observed, which may be associated with changes in access to timely diagnosis at the community level.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of the COVID-19 pandemic on surgical outcomes of lung cancer in a medium-burden region of Japan

  • 期刊论文

  • 发表日期：

    2026年3月23日

查看全文
  • Takafumi Kabuto,
  • Kaito Kitahori,
  • Masaki Ikeda,
  • Naohisa Chiba,
  • Masashi Ishikawa

摘要

Objectives

We aimed to investigate the impact of the coronavirus disease-2019 pandemic on the prognosis of patients undergoing lung cancer surgery in a medium-burden region.

Methods

We retrospectively reviewed patients undergoing lung cancer surgery at a Japanese designated cancer hospital. Three-year time-to-progression (TTP) and overall survival (OS) were compared between the prepandemic (January 2018–March 2020, n = 333) and pandemic (April 2020–June 2022, n = 350) period, including subgroups analyses by pathological stage. Referral trends for all lung cancer and suspected lung cancer patients were also examined.

Results

There were no significant differences between the prepandemic and pandemic periods (TTP: 77.9% vs. 80.4%, p = 0.578; OS: 86.1% vs. 86.3%, p = 0.916), nor in pStage 0–I (TTP: 88.1% vs. 89.9%, p = 0.529; OS: 90.1% vs. 91.0%, p = 0.660) or pStage II (TTP: 67.3% vs. 78.2%, p = 0.471; OS: 78.7% vs. 82.6%, p = 0.736). However, TTP and OS during the pandemic were significantly lower in pStage III (TTP: 49.4% vs. 31.5%, p = 0.045, OS: 73.3% vs. 71.8%, p = 0.890) and IV (TTP: 12.5% vs. 25.0%, p = 0.668, OS: 87.5% vs. 29.2%, p = 0.023), respectively. During the pandemic, outside-referrals markedly decreased, while in-hospital referrals increased.

Conclusions

While overall surgical outcomes remained stable, stage-specific analyses demonstrated worse outcomes in advanced-stage disease during the pandemic. A reduction in outside referrals during the pandemic was observed, which may be associated with changes in access to timely diagnosis at the community level.